Drug Interactions between Adempas and Entereg
This report displays the potential drug interactions for the following 2 drugs:
- Adempas (riociguat)
- Entereg (alvimopan)
Interactions between your drugs
No interactions were found between Adempas and Entereg. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Adempas
A total of 283 drugs are known to interact with Adempas.
- Adempas is in the drug class vasodilators.
- Adempas is used to treat Pulmonary Arterial Hypertension.
Entereg
A total of 38 drugs are known to interact with Entereg.
- Entereg is in the drug class peripheral opioid receptor antagonists.
- Entereg is used to treat the following conditions:
Drug and food interactions
riociguat food
Applies to: Adempas (riociguat)
ADJUST DOSE: Smoking may decrease the plasma concentrations of riociguat. The proposed mechanism is induction of the CYP450 1A1-mediated metabolism of riociguat by polycyclic aromatic hydrocarbons present in cigarette smoke. CYP450 1A1 is responsible for the formation of the major active metabolite, M1, which has just 1/3 to 1/10 the pharmacologic activity of riociguat. According to the product labeling, plasma concentrations of riociguat are reduced by 50% to 60% in smokers compared to nonsmokers.
MANAGEMENT: Riociguat dosages higher than 2.5 mg three times a day may be considered in cigarette smokers, if tolerated, so as to match the exposure seen in nonsmoking patients. However, safety and effectiveness of higher dosages have not been established. A dosage reduction should be considered in patients who stop smoking during treatment with riociguat.
References
- (2013) "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc
alvimopan food
Applies to: Entereg (alvimopan)
Coadministration with a high-fat meal may decrease the rate and extent of alvimopan absorption. According to the product labeling, alvimopan peak plasma concentration (Cmax) and systemic exposure (AUC) were decreased by approximately 38% and 21%, respectively, and the time to reach peak plasma concentration (Tmax) was prolonged by approximately 1 hour when taken with a high-fat meal. The clinical significance is unknown. In postoperative ileus clinical trials, the preoperative dose of alvimopan was administered in a fasting state, and subsequent doses were given without regard to meals.
References
- (2008) "Product Information. Entereg (alvimopan)." GlaxoSmithKline
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.